Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.

European journal of haematology - 1 Aug 2026

Caserta Santino, Martino Enrica Antonia, Vigna Ernesto, Skafi Mamdouh, Bruzzese Antonella, Amodio Nicola, Lucia Eugenio, D'Arrigo Graziella, Olivito Virginia, Labanca Caterina, Mendicino Francesco, Alvaro Maria Eugenia, Tripepi Giovanni, Morabito Fortunato, Gentile Massimo

Abstract excerpt

Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials. Despite these advances, MRD remains predominantly conceptualized as a quantitative variable reflecting residual tumor burden below assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Phenotype

Share to Prognosis

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 42036772
DOI: 10.1111/ejh.70203
PMCID: PMC13326799

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.PMID 42036772Read ↗

Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient ManagementSemantic proximity Read ↗

Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastomaSemantic proximity Read ↗

Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastomaSemantic proximity Read ↗

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapySemantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.Semantic proximity Read ↗

Molecular and cellular dynamics of measurable residual disease progression in myelodysplastic syndromesSemantic proximity Read ↗

NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemiaSemantic proximity Read ↗

Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Tumor heterogeneity makes AML a "moving target" for detection of residual disease.Semantic proximity Read ↗

Tumor heterogeneity makes AML a “moving target” for detection of residual diseaseSemantic proximity Read ↗

Adaptation and selection shape clonal evolution of tumors during residual disease and recurrenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.